

Facilitator's Guide for Exploring PsA and Reproductive Health

CASE BY CASE



Acknowledgements

These educational materials were supported by a medical education grant from Pfizer, Inc. to address Psoriatic Arthritis and Reproductive Health education to support patients, educators, and clinical teams.

Its contents are solely the responsibility of the authors and do not necessarily reflect the official views of Pfizer, Inc.

© 2021 American College of Rheumatology. All rights reserved.

ACRreprohealthinitiative.com

Authors

Mehret Birru Talabi, MD Linda Grinnell-Merrick, NP Sonam Kiwalkar, MD Arthur Kavanaugh, MD Vagishwari Murugesan, MD



American College of Rheumatology Empowering Rheumatology Professionals

Getting started

Exploring PsA and Reproductive Health, Case by Case was created by the American College of Rheumatology (ACR), to educate prescribing providers and their healthcare teams on how to manage and treat Psoriatic Arthritis (PsA) in patients of reproductive age. Utilizing the 2020 American College of Rheumatology (ACR) Guidelines for Reproductive Health in Rheumatic Disease as the foundation, this program will explore the importance of shared decision making with patients, medications compatible with pregnancy and lactation, as well as how to educate patients on how to prepare for the best pregnancy outcomes given their disease status. Using multiple case studies with women and men, this program will walk providers through the appropriate considerations, lab tests, and conversations that non-rheumatology and rheumatology providers should be aware of to provide the best care for their patients and their growing families.

Learning objectives

At the end of this presentation, learners will be able to:

- Discuss effects of Psoriatic Arthritis (PsA) on pregnancy
- Explain potential adverse pregnancy outcomes associated with PsA
- List the impact of drugs used in the treatment of PsA during pregnancy and lactation
- Recognize that women with PsA have a risk of flare post-partum
- Demonstrate successful use and integration of the ACR Reproductive Health in Rheumatic Diseases guidelines into patient care

What you need

- Computer and audio/visual equipment for projection of the PowerPoint presentation to the audience
- *Exploring PsA and Reproductive Health, Case by Case,* PowerPoint presentation
- Facilitator's Guide
- PsA Handouts (3)

Length of the activity

The presentation and discussion should last approximately 60 minutes, including time for Q&A. Plan for an additional 10 minutes for attendees to complete the post-test assessment, which can also be done up to 2 weeks after the session.

Importance of evaluation: the pre and post test


To continue to improve this education for others, it is important that we get feedback on:

- What are the participants learning from this session?
- How can this session be improved?
- What additional information would be helpful?

Your evaluations and insight allow the ACR to identify additional learner audiences and areas of interest regarding reproductive health and rheumatic disease.

Please be sure to encourage your learners to take the pre-test prior to the session, and the post-test at the completion of the session. If you have questions, please speak with your organization's point of contact.

Learning Objectives



Notes

READ the learning objectives as presented to the audience



SLIDE 5 Disease Overview

Psoriatic Arthritis (PsA) at a glance DISE

DISEASE OVERVIEW

PsA is a <u>chronic inflammatory arthritis</u> that occurs in some people with skin psoriasis

 (About 30% of people with psoriasis also develop PsA)

 PsA typically <u>affects the large joints</u>, especially those of the lower extremities, distal joints of the fingers and toes, and can affect the back and sacroiliac joints of the pelvis
 Though there is <u>no cure, there are treatments available</u> to help stop disease progression, lessen pain, protect joints and preserve a range of motion
 PsA can <u>occur due to complex interactions</u> between the environment and a genetically predisposed individual

American College «Rheumatology Psoriatic Arthritis and Reproductive Health

5

Notes

Read the disease overview as presented to the audience

() **Emphasize** there is no cure for Psoriatic Arthritis, but there are treatments available

Sources

"Psoriatic Arthritis." *Rheumatology.org*, American College of Rheumatology, Mar. 2019, www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis.

"What Is Psoriatic Arthritis?" Homepage: National Psoriasis Foundation, National Psoriasis Foundation, 2021, www.psoriasis.org/about-psoriatic-arthritis.

Arthritis Foundation. Arthritis By the Numbers. 2019; v3; 4100.17.10445, https://www.arthritis.org/getmedia/e1256607-fa87-4593-aa8a-8db4f291072a/2019-abtn-final-march-2019.pdf.

SLIDE 6 Common Symptoms

Psoriatic Arthritis (PsA) at a glance COMMON SYMPTOMS

Fatigue

Tenderness, pain and swelling over tendons

- □ Swollen fingers and toes
- Stiffness, pain, throbbing in one or more joints
- Reduced range of motion



© 2021 American College of Rheumatology. All rights reserved.

6

□ Nail changes, such as pitting or separation from the nail bed

American College Rheumatology Psoriatic Arthritis and Reproductive Health

Notes

Read the common symptoms as presented to the audience

Source

"What Is Psoriatic Arthritis?" Homepage: National Psoriasis Foundation, National Psoriasis Foundation, 2021, www.psoriasis.org/about-psoriatic-arthritis/.

SLIDE 7 Demographics

 PsA typically appears in people <u>between the ages of 30 and</u> but can begin as early as childhood <u>Men and women</u> are equally at risk of developing PsA People of <u>all races & ethnicities</u> can develop psoriasis and psoriatic arthritis 	oriatic Arthritis (Ps/ a glance	A) DEMOGRAPHICS
 Men and women are equally at risk of developing PsA People of <u>all races & ethnicities</u> can develop psoriasis and 		
	 Men and women are equal People of <u>all races & ethnic</u> 	ly at risk of developing PsA
CAN COLLEGE Psoriatic Arthrit		Psoriatic Arthritis and

Notes

 \blacksquare **Read** the demographics as presented to the audience

Source


"Psoriatic Arthritis." *Rheumatology.org*, American College of Rheumatology, Mar. 2019, www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis.

American College of Rheumatology Empowering Rheumatology Professionals

Tammy


Facilitator Note

In the following cases, conversations between patients and providers (represented by talk bubbles) have audio that will play automatically when the presentation is in PowerPoint SlideShow view. Each slide's audio will play automatically when you advance to the next slide.





slide 9 Meet Tammy




Notes

- Read Tammy's chart summary as presented to the audience
- () **Emphasize** Tammy's uncontrolled disease given her new diagnosis
- Facilitator Note: Click to the next slide and audio will begin automatically this audio represents the conversation between Tammy and her provider



SLIDE 10 Conversation




Notes

Facilitator Note: Audio for the conversation between Tammy and her provider will begin automatically



SLIDE 11 Conversation




Notes

Facilitator Note: Audio for the conversation between Tammy and her provider will begin automatically



SLIDE 12 Conversation




Notes

Facilitator Note: Audio for the conversation between Tammy and her provider will begin automatically



SLIDE 13 Conversation




Notes

🛞 **Facilitator Note:** Audio for the conversation between Tammy and her provider will begin automatically



SLIDE 14 Conversation



Notes

🛞 **Facilitator Note:** Audio for the conversation between Tammy and her provider will begin automatically


Click to the next slide once the conversation is complete. Audio for the conversation on the next slide will begin automatically

Source

"Psoriatic Arthritis." *Rheumatology.org*, American College of Rheumatology, Mar. 2019, www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis.

American College of Rheumatology Empowering Rheumatology Professionals

SLIDE 15 Conversation



Notes

🛞 **Facilitator Note:** Audio for the conversation between Tammy and her provider will begin automatically


Click to the next slide once the conversation is complete. Audio for the conversation on the next slide will begin automatically

Source

"Psoriatic Arthritis." *Rheumatology.org*, American College of Rheumatology, Mar. 2019, www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis.

American College of Rheumatology Empowering Rheumatology Professionals

SLIDE 16 Conversation




Notes

Facilitator Note: Audio for the conversation between Tammy and her provider will begin automatically



SLIDE 17 Conversation




Notes

🙊 **Facilitator Note:** Audio for the conversation between Tammy and her provider will begin automatically



SLIDE 18 Conversation




Notes

Facilitator Note: Audio for the conversation between Tammy and her provider will begin automatically



SLIDE 19 Birth Control Chart



Notes

(a) **Facilitator Note:** Audio for the conversation about the birth control chart will begin automatically.

Click to the next slide once the conversation is complete.

Source

"How Well Does Birth Control Work?" UCSF School of Medicine Bixby Center and Bedsider, Apr. 2019.

AMERICAN COLLEGE of RHEUMATOLOGY Empowering Rheumatology Professionals

Case 1 Learning Points

CASE 1 – TAMMY Learning Points



- PsA is an autoimmune condition resulting in inflammatory arthritis seen in approximately 30% of patients with Psoriasis
- A multi-faceted approach to pregnancy planning is essential in women of childbearing age as uncontrolled disease activity and medications used to treat the condition can result in adverse pregnancy outcomes

Psoriatic Arthritis and Reproductive Health

Notes

- **Read** case 1 learning points as presented to the audience
- () **Emphasize** a multi-faceted approach to pregnancy planning is important, especially for women with uncontrolled disease activity



CASE TWO




Facilitator Note

In the following cases, conversations between patients and providers (represented by talk bubbles) have audio that will play automatically when the presentation is in PowerPoint SlideShow view. Each slide's audio will play automatically when you advance to the next slide.





slide 22 Meet Lacee




Notes

- **Read** Lacee's chart summary as presented to the audience
- () **Emphasize** Lacee's current medications
- Facilitator Note: Click to the next slide and audio will begin automatically—this audio represents the conversation between Lacee and her provider



SLIDE 23 Conversation



Notes

Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically



SLIDE 24 Conversation




Notes

(a) Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically



SLIDE 25 Conversation




Notes

🙊 Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically



SLIDE 26 Conversation



Notes

(a) **Facilitator Note:** There is NO AUDIO for this slide. Read through each step of this handout as presented for the audience.


Click to the next slide once complete. Audio for the conversation on the next slide will begin automatically.

() **Emphasize** that you will first review steps for pregnancy planning, and shortly you will review medication compatibility

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.

SLIDE 27 Conversation




Notes

Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically



SLIDE 28 Medication List (Handout)



Notes

(a) **Facilitator Note:** There is NO AUDIO for this slide. Read through each step of this handout as presented for the audience.

Click to the next slide once complete. Audio for the conversation on the next slide will begin automatically.


() Emphasize green list medications are "good to go" and safe/compatible with pregnancy

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.

SLIDE 29

Pregnancy Planning - Step 2 & 3




Notes

Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically Click to the next slide once the conversation is complete.



SLIDE 30

Pregnancy Planning - Step 2 & 3



Notes

Facilitator Note: There is NO AUDIO for this slide. Mention that you just heard the provider discuss steps 2 and 3 of this process.


Click to the next slide once complete. Audio for the conversation on the next slide will begin automatically.

() **Emphasize** green list medications are "good to go" and safe/compatible with pregnancy

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.

SLIDE 31 Pregnancy Planning - Medications




Notes

Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically Click to the next slide once the conversation is complete.



SLIDE 32 Medication list (Handout)



Notes

(a) **Facilitator Note:** There is NO AUDIO for this slide. Read through each medication group of this handout as presented for the audience.

Click to the next slide once complete. Audio for the conversation on the next slide will begin automatically.

() **Emphasize** grey list medications need to be discussed with the rheumatologist, as they may or may not be a good fit for the patient

Emphasize red list medications should be stopped immediately, as they are not compatible with pregnancy

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.

SLIDE 33 Pregnancy Planning - Step 3 & 4




Notes

Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically Click to the next slide once the conversation is complete.



SLIDE 34

Pregnancy Planning - Step 3 & 4



Notes


(a) **Facilitator Note:** There is NO AUDIO for this slide. Read through steps 3 and 4 of this handout as presented for the audience, given the reference to the handout for men.

Click to the next slide once complete. Audio for the conversation on the next slide will begin automatically.

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.

SLIDE 35 Conversation




Notes

Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically.
Click to the next slide once complete. Audio for the conversation on the next slide will begin automatically.



SLIDE 36 Conversation



Notes

Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically. Click to the next slide once complete. Audio for the conversation on the next slide will begin automatically.



SLIDE 37 Conversation



Notes

Facilitator Note: Audio for the conversation between Lacee and her provider will begin automatically. Click to the next slide once complete. Audio for the conversation on the next slide will begin automatically.



SLIDE 38 Case 2 Learning Points

CASE 2 – LACEE Learning Points

- Contraception should be discussed with patients of childbearing age during their visits
- It is important to have the <u>conversation</u> with patients <u>about medications and their potential</u> <u>impacts</u> on their pregnancy

- **Read** case 2 learning points as presented to the audience
- () **Emphasize** the importance of talking with patients about their medications and the potential impacts of those medications on their pregnancies



Jack


Facilitator Note

In the following cases, conversations between patients and providers (represented by talk bubbles) have audio that will play automatically when the presentation is in PowerPoint SlideShow view. Each slide's audio will play automatically when you advance to the next slide.





slide 40 Meet Jack




Notes

(E) **Read** Jack's chart summary as presented to the audience



slide 41 Jack's File



- Read Jack's chart summary as presented to the audience
- () **Emphasize** Jack's swollen and tender joints, as well as his current medications, especially methotrexate




slide 42 Jack's Visit



- Read Jack's chart summary as presented to the audience
- () **Emphasize** Jack's desire to start a family with his wife
- Facilitator Note: Click to the next slide and audio will begin automatically—this audio represents the conversation between Jack and his provider



SLIDE 43 Conversation




Notes

Facilitator Note: Audio for the conversation between Jack and his provider will begin automatically.

Click to the next slide once the conversation is complete. Audio for the conversation on the next slide will begin automatically.



SLIDE 44 Conversation




Notes

Facilitator Note: Audio for the conversation between Jack and his provider will begin automatically.

Click to the next slide once the conversation is complete. Audio for the conversation on the next slide will begin automatically.



SLIDE 45 Conversation



Notes


🝥 **Facilitator Note:** Audio for the conversation between Jack and his provider will begin automatically.

Click to the next slide once the conversation is complete. Audio for the conversation on the next slide will begin automatically.

() **Emphasize** that there are some differences in terms of medication compatibility and reproductive health for men and women



SLIDE 46 Conversation



Notes


(a) **Facilitator Note:** Audio for the conversation between Jack and his provider will begin automatically.

Click to the next slide once the conversation is complete. Audio for the conversation on the next slide will begin automatically.

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.


SLIDE 47 Conversation



- Facilitator Note: Audio for the conversation between Jack and his provider will begin automatically. Click to the next slide once the conversation is complete.
- () **Emphasize** more recent consensus in the field is that stopping methotrexate is not necessary for men trying to father a child
- () **Emphasize** sulfasalazine should be avoided, as it can lower sperm counts



SLIDE 48 Pregnancy Planning - 4 Steps



Notes

(a) **Facilitator Note:** There is NO AUDIO for this slide. Read through each step of this handout as presented for the audience, given the reference to the handout for men.

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.

SLIDE 49 Medication List

MEN with Psoriatic Arthritis planning to father a child	 Medications to discuss with your rheumatologist Apremilast Abatacept Interleukin 17 inhibitor (Secukinumab, Ixekizumab) Interleukin 23 inhibitor (Guselkumab) Interleukin 12/23 inhibitor (Ustekinumab) Janus kinase inhibitors (Tofacitinib, Baricitinib, Upadacitinib) Leflunomide Methotrexate Non-steroidal anti-inflammatory agents Sulfasalazine Tumor necrosis factor inhibitors (TNFi) (TNFi = Adalimumab, Etanercept, Infliximab, Certolizumab, Golimumab)
	ications listed here appear to be safe in the context of family planning for heumatic disease. Discuss these medications with your rheumatologist. Psoriatic Arthritis and Reproductive Health 49

Notes

- Facilitator Note: There is NO AUDIO for this slide. Read through medication group of this handout as presented for the audience, noting that the only group is grey.
- () **Emphasize** all medications for men planning to father a child should be discussed with a rheumatologist

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.

CASE 3 – JACK Learning Points



Family planning is a discussion to have with male patients.

- (E) **Read** case 3 learning points as presented to the audience
- () **Emphasize** the importance of talking with male patients about family planning, especially how their medications will impact their plans



CASE FOUR

Facilitator Note

In the following cases, conversations between patients and providers (represented by talk bubbles) have audio that will play automatically when the presentation is in PowerPoint SlideShow view. Each slide's audio will play automatically when you advance to the next slide.






slide 52 Case 4 - Terri



- (E) Read case 3 learning points as presented to the audience
- () **Emphasize** that Terri is currently in her second trimester of pregnancy




slide 53 Terri's File



- **Read** Terri's chart summary as presented to the audience
- () **Emphasize** that this is Terri's first pregnancy, her disease is well-controlled, and there are some questions about some of her medications



slide 54 Terri's Visit



- Read Terri's chart summary as presented to the audience
- () **Emphasize** that Terri has many questions about medication safety, not only during pregnancy, but also during lactation/breastfeeding
- Facilitator Note: Click to the next slide and audio will begin automatically—this audio represents the conversation between Terri and her provider



SLIDE 55 Conversation




Notes

Facilitator Note: Audio for the conversation between Terri and her provider will begin automatically Click to the next slide once the conversation is complete



SLIDE 56 Conversation




Notes

Facilitator Note: Audio for the conversation between Terri and her provider will begin automatically Click to the next slide once the conversation is complete



SLIDE 57 Conversation




Notes

- Facilitator Note: Audio for the conversation between Terri and her provider will begin automatically Click to the next slide once the conversation is complete
- () **Emphasize** the FDA recommended in October 2020 that NSAIDs be stopped at 20 weeks of pregnancy, which is more specific than the ACR's guidelines

Source

Center for Drug Evaluation and Research. "Nsaids May Cause Rare Kidney Problems in Unborn Babies." U.S. Food and Drug Administration, FDA, www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding- use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic.

SLIDE 58 Conversation




Notes

Facilitator Note: Audio for the conversation between Terri and her provider will begin automatically Click to the next slide once the conversation is complete



SLIDE 59 Conversation




Notes

Facilitator Note: Audio for the conversation between Terri and her provider will begin automatically Click to the next slide once the conversation is complete

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.

SLIDE 60 Conversations




Notes

- Facilitator Note: Audio for the conversation between Terri and her provider will begin automatically Click to the next slide once the conversation is complete
- () **Emphasize** the general consensus is that medications that are safe during pregnancy are generally safe during lactation

Source

Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." *Arthritis & Rheumatology*, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.

SLIDE 61 Conversations




Notes

Facilitator Note: Audio for the conversation between Terri and her provider will begin automatically Click to the next slide once the conversation is complete



SLIDE 62 Conversations



Notes

Facilitator Note: Audio for the conversation between Terri and her provider will begin automatically Click to the next slide once the conversation is complete



SLIDE 63 Case 4 Learning Points

CASE 4 – TERRI Learning Points



One of the best things to ensure a healthy baby is to have a healthy mother


Medications that are safe during pregnancy are generally safe during lactation

> Psoriatic Arthritis and Reproductive Health

- **Read** case 4 learning points as presented to the audience
- () **Emphasize** that medications that are safe during pregnancy are generally safe during lactation



slide 64 Key Messages



- Read the key messages as presented to the audience
- **Facilitator Note:** These key messages are a summary from all four cases



slide 65 Key Messages




- **Read** the key messages as presented to the audience
- **Facilitator Note:** These key messages are a summary from all four cases



Pregnancy Planning for Women with Psoriatic Arthritis

For women living with Psoriatic Arthritis who are planning their pregnancy, it is important to review the following information with your provider.



- Use medications on
 GREEN LIST
- Keep your Psoriatic arthritis activity as low as possible

Is your Psoriatic arthritis well controlled?

- Minimal skin and nail Psoriasis
- Minimal signs of joint inflammation
- No recent signs/symptoms consistent with iritis, inflammatory bowel disease, enthesitis, dactylitis
- No flares in the last 6 months

Are your medications right for you at this time?

Continue or start
 GREEN LIST medications

7(

- Discuss with your doctor and talk about a switch from **RED LIST** meds to **GREEN LIST** meds
- Discuss any other medications with your obstetrician

Which doctors should you talk with?

- Rheumatology provider/ Dermatology provider
- Maternal-Fetal Medicine Specialist
- Local Obstetrician (OB)
- Dermatologist

04

Medications

🖉 GREEN LIST | Good to go

- Sulfasalazine
- Prednisone <20 mg a day
- Tumor necrosis factor inhibitors (TNFi)

(TNFi = Adalimumab, Etanercept, Infliximab, Certolizumab, Golimumab)



- Methotrexate
- Leflunomide

်း GREY LIST | Talk to the rheumatologist

- Janus kinase inhibitors (Tofacitinib, Baricitinib, Upadacitinib)
- Apremilast
- Abatacept
- Interleukin 17 inhibitor (Secukinumab, Ixekizumab)
- Interleukin 23 inhibitor (Guselkumab)
- Interleukin 12/23 inhibitor (Ustekinumab)
- Rituximab
- Non-steroidal anti-inflammatory agents (safe for use in 1st trimester, discuss with rheumatologist about discontinuing at 20 weeks of gestation*)
- *The FDA recommends considering discontinuation of NSAIDs at 20 weeks of gestation as of October 2020


These educational materials were supported by a medical education grant from GlaxoSmithKline to address Systemic Lupus Erythematosus (SLE) and Reproductive Health education to support patients, educators, and clinical teams. Its contents are solely the responsibility of the authors and do not necessarily reflect the official views of GlaxoSmithKline.

© 2021 American College of Rheumatology. All rights reserved.



Men with Psoriatic Arthritis Planning to Father a Child

For men living with Psoriatic Arthritis who are preparing to father a child, it is important to review the following information with your provider.



- Discuss medications with your rheumatologist
- Keep your Psoriatic Arthritis activity as low as possible

Is your Psoriatic arthritis well controlled?

- Minimal skin and nail Psoriasis
- Minimal signs of joint inflammation
- No recent signs/symptoms consistent with iritis, inflammatory bowel disease, enthesitis, dactylitis
- No flares in the last 6 months

Are your medications right for you at this time?

· Discuss medications with your rheumatologist

03

• Note: Sulfasalazine can decrease sperm count and quality

Which doctors should you talk with?

Rheumatology provider

04

Dermatology provider

Medications to discuss with your rheumatologist

- Apremilast
- Abatacept
- Interleukin 17 inhibitor (Secukinumab, Ixekizumab)
- Interleukin 23 inhibitor (Guselkumab)
- Interleukin 12/23 inhibitor (Ustekinumab)
- Janus kinase inhibitors (Tofacitinib, Baricitinib, Upadacitinib)

- Methotrexate • Non-steroidal anti-inflammatory agents
- Sulfasalazine
- Tumor necrosis factor inhibitors (TNFi) (TNFi = Adalimumab, Etanercept, Infliximab, Certolizumab, Golimumab)

Leflunomide

These educational materials were supported by a medical education grant from GlaxoSmithKline to address Systemic Lupus Erythematosus (SLE) and Reproductive Health education to support patients, educators, and clinical teams. Its contents are solely the responsibility of the authors and do not necessarily reflect the official views of GlaxoSmithKline.

© 2021 American College of Rheumatology. All rights reserved.



slide 66 References



- Arthritis Foundation. Arthritis By the Numbers. 2019; v3; 4100.17.10445
- Center for Drug Evaluation and Research. "Nsaids May Cause Rare Kidney Problems in Unborn Babies." U.S. Food and Drug Administration, FDA,
- www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic. "How Well Does Birth Control Work?" UCSF School of Medicine Bixby Center and Bedsider, Apr. 2019.
- Provide the second s
- Sammaritano, Lisa R, et al. "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases." Arthritis & Rheumatology, vol. 72, no. 4, Apr. 2020, pp. 529–556., doi:10.1002/art.41191.
- * "What Is Psoriatic Arthritis?" Homepage: National Psoriasis Foundation, National Psoriasis Foundation, 2021, www.psoriasis.org/about-psoriatic-arthritis/.

American College (Rheumatology Experience Researching Professional Psoriatic Arthritis and Reproductive Health







Notes

- (a) **Facilitator Note:** Field questions from attendees about the cases and other content.
- () Emphasize additional resources on <u>www.ACRreprohealthinitiative.com</u>

Emphasize the importance of the 2020 ACR Guidelines (which can be found in the resources section of <u>www.ACRreprohealthinitiative.com</u>)



SLIDE 68 Contact Info



Facilitator Notes

- Thank participants for attending *Exploring PsA and Reproductive Health, Case by Case*
- Remind participants about the importance of their feedback and emphasize that they take the post-test assessment. Allow 10 minutes for the post-test to be completed.
- If you are comfortable, consider offering your contact information to participants in case they have questions after today's session.



American College of Rheumatology Empowering Rheumatology Professionals